0000950170-24-002743.txt : 20240108
0000950170-24-002743.hdr.sgml : 20240108
20240108091034
ACCESSION NUMBER: 0000950170-24-002743
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240104
FILED AS OF DATE: 20240108
DATE AS OF CHANGE: 20240108
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: HSIAO JANE PH D
CENTRAL INDEX KEY: 0001188834
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33528
FILM NUMBER: 24518619
MAIL ADDRESS:
STREET 1: 4400 BISCAYNE BLVD
CITY: MIAMI
STATE: FL
ZIP: 33137
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: OPKO HEALTH, INC.
CENTRAL INDEX KEY: 0000944809
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 752402409
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 4400 BISCAYNE BLVD.
CITY: MIAMI
STATE: FL
ZIP: 33137
BUSINESS PHONE: 305-575-4181
MAIL ADDRESS:
STREET 1: 4400 BISCAYNE BLVD.
CITY: MIAMI
STATE: FL
ZIP: 33137
FORMER COMPANY:
FORMER CONFORMED NAME: Opko Health, Inc.
DATE OF NAME CHANGE: 20070621
FORMER COMPANY:
FORMER CONFORMED NAME: eXegenics Inc
DATE OF NAME CHANGE: 20040505
FORMER COMPANY:
FORMER CONFORMED NAME: EXEGENICS INC
DATE OF NAME CHANGE: 20011114
4
1
ownership.xml
4
X0508
4
2024-01-04
0000944809
OPKO HEALTH, INC.
OPK
0001188834
HSIAO JANE PH D
OPKO HEALTH, INC.
4400 BISCAYNE BLVD.
MIAMI
FL
33137
true
true
false
false
Vice Chairman & CTO
false
Common Stock
2024-01-05
4
P
false
150010
0.8726
A
27849880
D
Common Stock
5127404
I
See Footnote
5% Convertible Notes due 2025
1.66
2024-01-04
4
D
false
5000000
D
2025-01-31
Common Stock
5000000
0
D
3.75% Convertible Notes due 2029
1.15
2024-01-04
4
A
false
6452000
A
2028-09-15
2029-01-15
Common Stock
6452000
6452000
D
The securities are owned directly by Hsu Gamma Investment, L.P. Dr. Hsiao is the general partner of Hsu Gamma Investment, L.P. The reporting person disclaims beneficial ownership of these securities, except to the extent of any pecuniary interest therein and this report shall not be deemed an admission that the reporting person is the beneficial owner of the securities for purposes of Section 16 or for any other purpose.
The 5% Convertible Promissory Notes due 2025 were originally entered into on February 27, 2018 and the Reporting Person had the option to convert all or any portion of the outstanding principal balance of such original notes, plus unpaid interest, into shares of the Issuer's (as defined below) common stock, par value $0.01 per share, at a conversion price of $5.00 per share, at any time prior to the maturity date, which was February 27, 2023. Pursuant to an amendment on February 10, 2023, the maturity date was extended to January 31, 2025, which amendment also reset the conversion price to the 10 day volume weighted average price immediately preceding the date of such amendment, plus a 25% conversion premium, or $1.66.
Prior to September 15, 2028, holders of the 3.75% Convertible Senior Notes due 2029 will have the right to convert such notes only in certain circumstances and during specified periods and thereafter, will be convertible at the option of the holder at any time prior to the close of business on the business day immediately preceding January 15, 2029, the maturity date.
The reporting person entered into a Convertible Note Purchase Agreement with OPKO Health, Inc. (the "Issuer") on January 4, 2024, pursuant to which the reporting person disposed of $5,000,000 aggregate principal amount of 5% Convertible Promissory Notes due 2025, and accrued and unpaid interest thereon, in exchange for $6,452,000 aggregate principal amount of the Issuer's 3.75% Convertible Senior Notes due 2029 in a private placement.
Steven D. Rubin, Attorney-in-Fact
2024-01-08